Company intelligence / Profile preview
Mydecine Innovations Group
Vancouver, British Columbia, Canadamydecine.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Mydecine has developed a pipeline of novel psychedelic-derived therapeutics targeting mental health and addiction. Early clinical results from collaborations—such as Johns Hopkins' psilocybin smoking cessation study—showed promising efficacy with an ~80% abstinence rate at six months for psilocybin-assisted therapy. Most proprietary compounds remain in preclinical or IND-enabling stages, with plans for human trials commencing from 2024 onward.[1][3]
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (psychedelic compounds, tryptamines, entactogens)Novel chemical entities (NCEs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Applied Pharmaceutical Innovation at University of Alberta – R&D infrastructure and AI drug discovery partnership[6]
Beyond the preview
Go deeper on Mydecine Innovations Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mydecine Innovations Group.